Pyxis Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	11.14	180.77	276.21	8.08	19.69
Short-Term Investments	109.63	0	0	0	0
Cash & Cash Equivalents	120.77	180.77	276.21	8.08	19.69
Cash Growth	-33.19%	-34.55%	3318.40%	-58.96%	-
Other Current Assets	3.83	5.85	2.47	0.02	0.01
Total Current Assets	124.6	186.61	278.67	8.1	19.7
Property, Plant & Equipment	24.81	24.77	1.24	1.94	0.08
Goodwill and Intangibles	24.31	0	0	0	0
Other Long-Term Assets	0	0	0.11	0.11	0.03
Total Long-Term Assets	49.12	24.77	1.35	2.05	0.11
Total Assets	173.73	211.38	280.02	10.15	19.81
Accounts Payable	3.9	7.1	11.95	1.08	0.49
Deferred Revenue	7.66	0	0	0	0
Current Debt	1.23	0	0.17	0.62	0.01
Other Current Liabilities	12.97	24.54	6.59	2	0.23
Total Current Liabilities	25.76	31.63	18.71	3.69	0.73
Long-Term Debt	20.1	18.92	0	0.17	0.01
Other Long-Term Liabilities	2.16	0	0	0	0
Total Long-Term Liabilities	22.26	18.92	0	0.17	0.01
Total Liabilities	48.02	50.56	18.71	3.85	0.74
Total Debt	21.33	18.92	0.17	0.78	0.02
Debt Growth	12.74%	11367.27%	-78.85%	5100.00%	-
Retained Earnings	-286.23	-212.44	-91.72	-15.74	-2.92
Comprehensive Income	0.06	0	0	0	0
Shareholders' Equity	125.7	160.82	261.31	-15.65	-2.87
Net Cash / Debt	99.44	161.84	276.04	7.3	19.68
Net Cash / Debt Growth	-38.56%	-41.37%	3681.40%	-62.90%	-
Net Cash Per Share	2.49	4.90	32.50	7.08	4.61
Working Capital	98.85	154.98	259.97	4.41	18.97
Book Value Per Share	3.15	4.87	30.77	-15.18	-0.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).